On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the installation of three additional drug substance manufacturing lines at Lonza’s Visp (CH) site. This doubled the existing drug substance production for COVID-19 Vaccine Moderna at the site.

In May 2020, Lonza and Moderna announced a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional Moderna products in the future.